Clobazam

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Clobazam is a 1,5-benzodiazepine with established global use as an antiepileptic and anxiolytic agent, including FDA-approved adjunctive treatment for Lennox-Gastaut syndrome (2011). The TxGNN model predicts it may be effective for febrile infection-related epilepsy syndrome (FIRES), with 0 clinical trials and 2 publications currently supporting this specific direction.

Quick Overview

Item	Content
Original Indication	Epilepsy (adjunctive therapy incl. Lennox-Gastaut syndrome) and anxiety — not registered in the Netherlands
Predicted New Indication	Febrile infection-related epilepsy syndrome (FIRES)
TxGNN Prediction Score	99.82%
Evidence Level	L4
NL Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on information embedded in the evidence literature, Clobazam is a 1,5-benzodiazepine that enhances GABA-A receptor function with a known preference for the α2 subtype. This mechanism reduces cortical and subcortical hyperexcitability, forming the pharmacological basis for its broad use across epilepsy syndromes — from focal seizures to severe developmental epileptic encephalopathies such as Lennox-Gastaut syndrome and Dravet syndrome.

FIRES is a catastrophic form of new-onset refractory status epilepticus (NORSE) that primarily affects previously healthy children and adolescents. During the acute phase, intravenous benzodiazepines — in particular midazolam — are a cornerstone of seizure suppression. The TxGNN prediction rests on a plausible class-level inference: oral clobazam, as a 1,5-BZD, could theoretically serve as a transitional weaning agent when patients are being stepped down from IV anaesthetic management toward oral maintenance therapy. This pathway has biological coherence given shared GABA-A receptor targets.

However, the available literature does not study clobazam directly in FIRES. The two identified publications focus on enteral lorazepam (PMID 35770765) and perampanel (PMID 39958143) as weaning strategies — clobazam is not the primary subject in either. This prediction therefore represents a BZD class-effect extrapolation, not drug-specific evidence, which appropriately constrains the evidence level to L4.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35770765	2022	Case series	Epileptic Disorders	Enteral lorazepam used as effective weaning substitute for midazolam in FIRES patients; supports the BZD class weaning concept but does not study clobazam directly
39958143	2025	Case report	Cureus	Perampanel reduced barbiturate dependency in a 13-year-old with FIRES; highlights need for non-anaesthetic alternatives — clobazam not evaluated

Netherlands Market Information

Clobazam currently holds no CBG-MEB marketing authorization in the Netherlands. There are 0 registered products containing clobazam in the Dutch medicines registry. Any clinical use in the Netherlands would require a patient-level special authorization (Article 3.17 Geneesmiddelenwet) or a named-patient importation route under applicable regulatory provisions. The absence of a Dutch SmPC means safety and dosing guidance must be sourced from the EMA product information or the FDA-approved SmPC (Onfi®).

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for full safety information. Given the absence of a Dutch CBG-MEB authorization, the EMA SmPC for clobazam (where available) or the FDA SmPC for Onfi® is the recommended reference document.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.82%), the supporting evidence for clobazam specifically in FIRES consists of only 2 publications — neither of which directly investigates clobazam — and 0 registered clinical trials. The mechanistic rationale is biologically plausible as a benzodiazepine class effect, but drug-specific clinical validation is absent.

To proceed, the following is needed:

Direct clinical data on clobazam in FIRES: a prospective case series or observational study specifically evaluating clobazam as a weaning or maintenance agent
Safety and pharmacokinetic profiling in the FIRES population (critically ill, predominantly pediatric, often on concurrent anaesthetics)
Regulatory pathway assessment: clobazam is not authorized in the Netherlands; a Named Patient / hospital exemption pathway via CBG-MEB must be established before any trial use
Mechanism of action documentation: DrugBank API query to resolve the current data gap (DG002) and support mechanistic plausibility analysis
Safety review to resolve DG001: Dutch or EMA SmPC warnings and contraindications must be obtained before entering formal safety evaluation (currently blocking S1 stage)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.